Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis PharmaTimesLead candidate ETD001 delivers significant lung function improvementRespiratoryRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) PharmaTimes Lead candidate ETD001 delivers significant lung function improvement Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellular Intelligence scoops up Novo’s Parkinson’s therapyNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
